These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19020367)

  • 1. Anthracycline-induced cardiomyopathy.
    Simmons A; Vacek JL; Meyers D
    Postgrad Med; 2008 Nov; 120(4):67-72. PubMed ID: 19020367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
    Silber JH
    Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapeutics-induced heart failure].
    Paulides M; Wojnowski L
    Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.
    Zuppinger C; Timolati F; Suter TM
    Cardiovasc Toxicol; 2007; 7(2):61-6. PubMed ID: 17652805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
    Granger CB
    Circulation; 2006 Dec; 114(23):2432-3. PubMed ID: 17146002
    [No Abstract]   [Full Text] [Related]  

  • 8. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J; Wasserheit C
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy.
    Jahangir E; Shah S; Shum K; Baxter C; Fitzpatrick JD; Cole J; Gilliland Y; Polin NM
    South Med J; 2015 Feb; 108(2):71-8. PubMed ID: 25688890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.
    Temming P; Qureshi A; Hardt J; Leiper AD; Levitt G; Ancliff PJ; Webb DK
    Pediatr Blood Cancer; 2011 Apr; 56(4):625-30. PubMed ID: 21298750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
    Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
    Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of late-onset anthracycline cardiomyopathy.
    Bernaba BN; Chan JB; Lai CK; Fishbein MC
    Cardiovasc Pathol; 2010; 19(5):308-11. PubMed ID: 19747852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.
    Adams MJ; Lipshultz SE
    Pediatr Blood Cancer; 2005 Jun; 44(7):600-6. PubMed ID: 15856486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-induced cardiomyopathy.
    Keefe DL
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.